相关实验视频

Updated: Jul 13, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

在三阴性乳腺癌中PD-1/PD-L1抑制剂反应:长非编码RNA可以关联吗?

Carolina Mathias¹, Vanessa Nascimento Kozak¹, Jessica Maria Magno²

¹Post-Graduation Program in Genetics, Department of Genetics, Federal University of Parana, Curitiba 81530-980, Brazil.

|October 14, 2023

概括

长非编码RNAs (lncRNAs) 作为预测癌症中对免疫检查点抑制剂 (ICI) 的反应的生物标志物具有前景. 这次审查强调了UCA1和HCP5作为三阴性乳腺癌 (TNBC) 免疫治疗的潜在生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

免疫检查点抑制剂 (ICI) 正在彻底改变癌症治疗,但需要有效的生物标志物来预测患者的反应.
三阴性乳腺癌 (TNBC) 缺乏特定的治疗点,目前的生物标志物如PD-L1状态不足以指导ICI治疗.
长非编码RNAs (lncRNAs) 越来越多地被认为是它们在癌症和免疫调节中的作用.

研究的目的:

审查lncRNAs在调节PD-1/PD-L1通路中的作用及其作为预后生物标志物的潜力.
通过生物信息分析识别用于预测TNBC中的ICI反应的新型lncRNA候选者.
突出 lncRNAs 作为免疫治疗的多功能生物标志物的潜力.

主要方法:

关于lncRNAs,PD-1/PD-L1通路和癌症生物标志物的综合文献综述.
在各种癌症类型中参与PD-1/PD-L1通路的lncRNAs的生物信息分析.
专注于三阴性乳腺癌 (TNBC) 的分子背景.

主要成果:

lncRNAs在调节PD-1/PD-L1免疫检查点路径方面发挥着重要作用.
生物信息分析确定UCA1和HCP5是TNBC中ICI反应的潜在 lncRNA生物标志物.
这些lncRNAs以前没有与乳腺癌的瘤免疫反应有关.

结论:

lncRNAs代表了一个有前途的分子类别,用于开发新的生物标志物以指导ICI治疗.
作为TNBC患者接受免疫治疗的潜在预测生物标志物,UCA1和HCP5需要进一步研究.
这项研究强调了 lncRNAs 在癌症免疫疗法和生物标志物发现中的多功能性.

关键词:

在HCP5中,HCP5是指HCP5.在UCA1中,UCA1是UCA1的.免疫反应的免疫反应.免疫疗法免疫疗法瘤微环境是一个微环境.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...